At 24 weeks, 32 and 29 percent of patients in the 9-mg and 18-mg groups had clinical benefit<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Feb. 27, 2024 (HealthDay News) — The oral selective androgen receptor modulator enobosarm has antitumor activity and can yield clinical benefit in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, according to a study published online Feb. 8 in The Lancet Oncology<\/em>.<\/p>\n Carlo Palmieri, M.B.B.S., Ph.D., from The Clatterbridge Cancer Centre NHS Foundation Trust in Liverpool, England, and colleagues examined the activity and safety of enobosarm in women with ER-positive, HER2-negative, and androgen receptor (AR)-positive disease. Postmenopausal women with previously treated ER-positive, HER2-negative, locally advanced or metastatic breast cancer were enrolled in a randomized trial conducted at 35 centers in nine countries. Participants were randomly allocated to receive 9 mg or 18 mg of oral enobosarm daily (72 and 64 patients, respectively). The evaluable population included 50 and 52 patients, respectively).<\/p>\n Patients were followed for a median of 7.5 months. The researchers found that 32 and 29 percent of the patients in the 9-mg and 18-mg groups, respectively, had clinical benefit at 24 weeks. Overall, 8 and 16 percent of those receiving 9 mg and 18 mg, respectively, had grade 3 or grade 4 drug-related adverse events, most frequently increased hepatic transaminases, hypercalcemia, and fatigue.<\/p>\n “The data from this study provide proof-of-concept for the activity and safety of a novel selective AR modulator, enobosarm, in AR-positive, ER-positive, and HER2-negative metastatic breast cancer, thus supporting the premise that activating AR can exert antitumor effects,” the authors write.<\/p>\n Several authors disclosed ties to pharmaceutical companies, including Veru, which manufactures enobosarm; the study was funded by GTx, which originally developed enobosarm.<\/p>\n Abstract\/Full Text<\/a><\/p>\n Editorial (subscription or payment may be required<\/a>)<\/p>\n <\/i><\/p>\n